Blincyto (blinatumomab) data shows benefit in Phase 2 trial in all patients with persistent or recurrent minimal residual disease

Amgen has announced that new data from three Phase 2 trials support the efficacy and safety of BLINCYTO® (blinatumomab) in adults with acute lymphoblastic leukemia (ALL). Source link